Products
2,497 Brands 483 Categories All Departments
not yet rated review & rate

Product No Longer Available

Unfortunately BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg is no longer carried by OpticsPlanet. You can also explore other items in the Laboratory Media category yourself to try and find the perfect replacement for you!

BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg Product Info

BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics Doxycycline, 30 µg is a reliable and dependable addition to the BD Laboratory Media family of products. Combining top-notch and uncompromising quality with an affordable price, the BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics Doxycycline, 30 µg 230777/ 90002-076 can fulfill your laboratory needs while still offering a great value for the money.

Product Category Description:

Antibiotics and Antimycotics—Amikacin to Nitrofurantoin, BD Diagnostics

This collection of media products is used for the qualitative susceptibility testing of mycobacteria and related organisms. These items provide a reliable, convenient, and rapid method for the evaluation of susceptibility of microorganisms to anti-microbial agents.

Ordering Information: Each test includes 50 susceptibility disks per cartridge.

Specifications for BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg:

Description:  Doxycycline, 30 µg
BD No.:  230777

BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg Related Products

BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg Unorderable Models

BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg, MPN: 230777, Code: B4-ME-230777

BD Antibiotics and AntimycoticsAmikacin to Nitrofurantoin, BD Diagnostics 230777 Doxycycline, 30 µg Comments